Emory University

Georgia Tech Research Corporation

Sruthi Ravindranathan

Edmund K Waller

Susan Thomas

Rebecca Pankove

Jian-Ming Li

Yiwen Li

David Francis

This disclosure relates to VIP antagonist for uses in managing the treatment or prevention of cancer and viral infections. In certain embodiments, this disclosure relates to chimeric variants of VIP antagonists, as peptides disclosed herein, and pharmaceutical composition comprising the same. In certain embodiments, this disclosure contemplates methods of stimulating immune cells to target cancer by mixing immune cells in vitro with peptides disclosed herein and further administering an effective amount of stimulated immune cells to a subject in need of cancer treatment.

Compositions and uses of vasoactive intestinal peptide (VIP) antagonists

This disclosure relates to compositions comprising an antagonist of vasoactive intestinal polypeptide signaling coupled to a nanoparticle and methods of use related thereto. In certain embodiments, the nanoparticle is a poloxamer-stabilized polypropylene sulfide nanoparticle.

Nanoparticles conjugated with vasoactive intestinal peptide antagonists

This disclosure relates to methods of treating cancer or viral infections comprising administering an effective amount of a VIP antagonist in combination with an immune check-point inhibitor to a subject in need thereof. In certain embodiments, the immune check-point inhibitor is an anti-PD1 or anti-PDL1 antibody.

VIP antagonists and uses in treating cancer

Growing community of inventors

Atlanta, GA, United States of America

Sruthi Ravindranathan